Perturbation of proteasome function by bortezomib leading to ER stress-induced apoptotic cell death in cholangiocarcinoma (Q47955863)

7 February 2018

title

Perturbation of proteasome function by bortezomib leading to ER stress-induced apoptotic cell death in cholangiocarcinoma (English)

1 reference

7 February 2018

0 references

1 reference

Kulthida Vaeteewoottacharn

1

1 reference

7 February 2018

Ryusho Kariya

2

1 reference

7 February 2018

Kouki Matsuda

3

1 reference

7 February 2018

Manabu Taura

4

1 reference

7 February 2018

Chaisiri Wongkham

5

1 reference

7 February 2018

Sopit Wongkham

6

1 reference

7 February 2018

Seiji Okada

7

1 reference

7 February 2018

publication date

23 July 2013

1 reference

7 February 2018

Journal of Cancer Research and Clinical Oncology

published in

1 reference

7 February 2018

volume

139

1 reference

7 February 2018

issue

9

1 reference

7 February 2018

page(s)

1551-1562

1 reference

7 February 2018

Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1473-6

Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1473-6

A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1473-6

Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1473-6

Bortezomib induces in HepG2 cells IkappaBalpha degradation mediated by caspase-8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1473-6

Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1473-6

Intrinsic capacities of molecular sensors of the unfolded protein response to sense alternate forms of endoplasmic reticulum stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1473-6

Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1473-6

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1473-6

Targeting the endoplasmic reticulum-stress response as an anticancer strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1473-6

Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1473-6

Proteasome inhibitor interacts synergistically with autophagy inhibitor to suppress proliferation and induce apoptosis in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1473-6

Analysis of the XBP1 splicing mechanism using endoplasmic reticulum stress-indicators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1473-6

A transgenic mouse model for monitoring endoplasmic reticulum stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1473-6

Blocking autophagy prevents bortezomib-induced NF-κB activation by reducing I-κBα degradation in lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1473-6

Comparison of gene expression profiles between Opisthorchis viverrini and non-Opisthorchis viverrini associated human intrahepatic cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1473-6

Synergistic effects of nelfinavir and bortezomib on proteotoxic death of NSCLC and multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1473-6

Endoplasmic reticulum stress: signaling the unfolded protein response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1473-6

Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1473-6

The role of the unfolded protein response in tumour development: friend or foe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1473-6

Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1473-6

The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1473-6

Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1473-6

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1473-6

Direct association of unfolded proteins with mammalian ER stress sensor, IRE1β

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1473-6

Early development of human hematopoietic and acquired immune systems in new born NOD/Scid/Jak3null mice intrahepatic engrafted with cord blood-derived CD34 + cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1473-6

Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1473-6

Cholangiocarcinoma--controversies and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1473-6

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1473-6

Role of ATF4 in regulation of autophagy and resistance to drugs and hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1473-6

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1473-6

Rapid degradation of a large fraction of newly synthesized proteins by proteasomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1473-6

Cepharanthine exerts antitumor activity on cholangiocarcinoma by inhibiting NF-kappaB.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1473-6

Intra-hepatic cholangiocarcinoma--frequency and demographic patterns: thirty-year data from the M.D. Anderson Cancer Center

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1473-6

Elevated plasma IL-6 associates with increased risk of advanced fibrosis and cholangiocarcinoma in individuals infected by Opisthorchis viverrini

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1473-6

Determination of subcutaneous tumor size in athymic (nude) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1473-6

Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1473-6

The predator becomes the prey: regulating the ubiquitin system by ubiquitylation and degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1473-6

Proteasome inhibition: a new therapeutic strategy to cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1473-6

PKCδ regulates death receptor 5 expression induced by PS-341 through ATF4-ATF3/CHOP axis in human lung cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1473-6

Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-013-1473-6

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

21 January 2018

1 reference

12 December 2020

Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer.

1 reference

12 December 2020

Proteasome inhibition-induces endoplasmic reticulum dysfunction and cell death of human cholangiocarcinoma cells

1 reference

12 December 2020

Surgery and chemotherapy for intrahepatic cholangiocarcinoma.

1 reference

12 December 2020

Bortezomib: proteasome inhibition as an effective anticancer therapy

1 reference

12 December 2020

Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (KKU-100).

1 reference

12 December 2020

Ubiquitin and the control of protein fate in the secretory and endocytic pathways

1 reference

12 December 2020

Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts.

1 reference

12 December 2020

10.1007/S00432-013-1473-6

Identifiers

DOI

1 reference

7 February 2018

1 reference

7 February 2018